Isoeugenol

Also known as Isoeugenol, 2-Methoxy-4-(1-propen-1-yl)phenol, 2-Methoxy-4-propenylphenol, 4-Hydroxy-3-methoxy-1-propenylbenzene, 4-Hydroxy-3-methoxy-beta-methylstyrene, 4-Propenylguaiacol, Phenol, 2-methoxy-4-(1-propenyl)-

Isoeugenol (CAS 97-54-1; 2-methoxy-4-(prop-1-enyl)phenol; C10H12O2) is the propenyl-substituted methoxyphenol isomer of eugenol (eugenol is the allyl-substituted analogue). Trade material is predominantly the trans (E) isomer (CAS 5932-68-3; 82-88% per SCCS/1459/11 p. 200), with cis (Z) isomer (CAS 5912-86-7) as a minor constituent. Isoeugenol is a long-established fragrance allergen on the original 26-substance list regulated under EU Cosmetics Regulation 1223/2009 Annex III Reference 73, requiring label declaration above 0,001% in leave-on and 0,01% in rinse-off products AND carrying a hard maximum-use cap of 0,02% in non-oral products — a stricter restriction than most other Annex III fragrance allergens (which are labeling-only) reflecting isoeugenol's higher sensitisation potency. The SCCS opinion SCCS/1459/11 (2012) classifies Isoeugenol in Table 13-1 (p. 107) as an established contact allergen in humans with a +++ rating (101-1000 published positive patch test cases) and asterisks it as a 1999 SCCNFP-listed allergen; Table 13-5 (p. 114) places it among the 12 single-chemical established fragrance allergens of special concern. Critically, SCCS/1459/11 Section 13.3 / Table 13-6 (p. 118-119) classifies Isoeugenol as an established PROHAPTEN of clinical importance — bioactivated by skin enzymatic oxidation, with NO mark in the 'Activation by air oxidation' column. This distinguishes Isoeugenol mechanistically from prehapten allergens like Limonene and Linalool: Isoeugenol does NOT have a peroxide cap recommendation in SCCS/1459/11 (the 10 ppm peroxide guidance is for hydroperoxide-forming prehaptens). The mechanistic basis comes from Bertrand et al. 1997 (Chem Res Toxicol, PMID 9084914): Isoeugenol acts via direct enzymatic oxidation to a para-quinone methide WITHOUT the O-demethylation step that Eugenol's ortho-quinone pathway requires — a mechanistically distinct prohapten pathway. More recent work by Ahn, Avonto, Chittiboyina and colleagues (PMID 32119530 in 2020 and PMID 37042673 in 2023) has identified diastereomeric 7,4'-oxyneolignan dimers as additional thiol-reactive isoeugenol oxidation products and proposed a hydroxy quinone methide as the actual reactive intermediate, suggesting isoeugenol may also possess prehapten character via autoxidation/degradation — but the binding SCCS regulatory classification remains prohapten-only. Per-ingredient patch test data (SCCS/1459/11 p. 200) show 1.3-5.4% positive reactions across multiple consecutive-tested European dermatology populations: IVDK 2007 1.3% (n=2063); Groningen 2009 1.3% at 2% pet.; Wöhrl 2001 5.4% (n=747); St Johns 2001-2005 with incremental year-on-year incidence reaching 2.67%; IVDK 2010 1.62% (n=1214) consecutively / 3.41% (n=5747) aimed-tested; Alicante extended fragrance series 11/86 (12.8%). Isoeugenol is one of only four substances (with HICC, cinnamal, and hydroxycitronellal) for which the SCCS judged dose-response data exist (p. 115) — although insufficient to derive an individual safe threshold. Cross-reactivity with isoeugenyl acetate is documented: White et al. 1999 (PMID 10554062) demonstrated that the majority of isoeugenol-allergic patients were also intolerant of isoeugenyl acetate, ruling it out as a safer replacement; a similar relationship is encoded in SCCS/1459/11 Section 13.4 conclusions which list isoeugenyl acetate as needing equivalent regulatory treatment to isoeugenol. The RIFM Expert Panel safety assessment (Api et al. 2016, PMID 26723296, FCT 97(S1):S49-S56) integrates these data into a comprehensive industry safety profile: repeated-dose NOAEL 37.5 mg/kg/day with MOE 5,769 (assuming 38.4% dermal absorption and 100% inhalation absorption), supporting continued use within QRA-derived limits and IFRA Standards. CIR has NOT published a standalone Isoeugenol assessment — verified absent by alphabetical traversal of the September 2022 CIR Quick Reference Table (alphabetically: Isodecyl Stearate → Isododecane → Isoeicosane → Isohexadecane, with no Isoeugenol row in between), consistent with CIR's deferral of pure fragrance ingredients to RIFM/IFRA/SCCS.